ImageneBio, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ImageneBio, Inc. (IMA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 5.10% for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Expense Statement
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2022-03-17
- ImageneBio, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 5.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2020-12-31 | 5.10% 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |